A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2018
At a glance
- Drugs Taladegib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 17 Feb 2018 Results (n=19) assessing safety, tolerability and pharmacokinetics of LY 2940680 in Japanese patients with advanced solid tumours, were published in the Investigational New Drugs.
- 09 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2017.
- 29 Aug 2016 Status changed from recruiting to active, no longer recruiting.